First United Bank & Trust Has $1.36 Million Position in Amgen Inc. (NASDAQ:AMGN)

First United Bank & Trust cut its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,389 shares of the medical research company’s stock after selling 95 shares during the period. First United Bank & Trust’s holdings in Amgen were worth $1,359,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. IAM Advisory LLC acquired a new position in Amgen in the 3rd quarter valued at about $809,000. Portland Global Advisors LLC lifted its holdings in shares of Amgen by 6.6% during the 3rd quarter. Portland Global Advisors LLC now owns 19,185 shares of the medical research company’s stock worth $4,080,000 after acquiring an additional 1,187 shares during the period. Adams Asset Advisors LLC lifted its holdings in shares of Amgen by 4.5% during the 3rd quarter. Adams Asset Advisors LLC now owns 34,493 shares of the medical research company’s stock worth $7,334,000 after acquiring an additional 1,498 shares during the period. Jacobs & Co. CA increased its position in Amgen by 12.4% during the 3rd quarter. Jacobs & Co. CA now owns 46,022 shares of the medical research company’s stock worth $9,786,000 after purchasing an additional 5,064 shares in the last quarter. Finally, Butensky & Cohen Financial Security Inc. increased its position in Amgen by 10.4% during the 3rd quarter. Butensky & Cohen Financial Security Inc. now owns 14,782 shares of the medical research company’s stock worth $3,143,000 after purchasing an additional 1,392 shares in the last quarter. Institutional investors own 74.95% of the company’s stock.

AMGN has been the topic of several research analyst reports. Barclays cut their target price on shares of Amgen from $230.00 to $228.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 3rd. BMO Capital Markets began coverage on shares of Amgen in a research note on Thursday, November 18th. They issued a “market perform” rating and a $228.00 price objective on the stock. Robert W. Baird reaffirmed a “sell” rating on shares of Amgen in a research note on Thursday, October 28th. Royal Bank of Canada dropped their price objective on shares of Amgen from $217.00 to $216.00 and set a “sector perform” rating on the stock in a research note on Wednesday, November 3rd. Finally, SVB Leerink dropped their price objective on shares of Amgen from $234.00 to $216.00 and set a “market perform” rating on the stock in a research note on Wednesday, November 3rd. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $235.50.

Shares of Amgen stock opened at $203.97 on Thursday. The stock has a market cap of $114.89 billion, a price-to-earnings ratio of 21.01, a PEG ratio of 1.47 and a beta of 0.61. The firm’s 50-day moving average is $209.99 and its 200 day moving average is $227.76. Amgen Inc. has a 1 year low of $200.47 and a 1 year high of $276.69. The company has a debt-to-equity ratio of 4.05, a current ratio of 1.64 and a quick ratio of 1.36.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, November 2nd. The medical research company reported $4.67 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $4.22 by $0.45. Amgen had a net margin of 21.77% and a return on equity of 108.67%. During the same quarter in the previous year, the company posted $4.37 EPS. On average, equities analysts expect that Amgen Inc. will post 16.83 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 8th. Investors of record on Tuesday, November 16th will be issued a $1.76 dividend. This represents a $7.04 annualized dividend and a yield of 3.45%. The ex-dividend date of this dividend is Monday, November 15th. Amgen’s dividend payout ratio is 72.50%.

Amgen Profile

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.

Read More: Fundamental Analysis – How It Helps Investors

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.